Monday, March 28, 2016

Mammograms May Detect More Than Breast Cancer



New study finds calcium deposits in breast tissue can predict calcium in arteries, a known risk factor for heart disease.

Mammograms are widely and often successfully used to detect breast cancer, the second leading cause of cancer death among U.S. women. Now, new research published in the journal JACC: Cardiovascular Imaging suggests it can help protect against an even bigger threat to women: cardiovascular disease.

Researchers believe breast calcification — small calcium deposits in the blood vessels found in breast tissue — is a good indicator of coronary arterial calcification, a very early sign of cardiovascular disease, Newsweek reported. Calcium narrows the arteries, which can increase the risk for heart attack. In breasts, though, calcium is very common and generally benign.

Doctors currently use CT scans to check for calcium deposits in arteries; however, scientists and doctors disagree that the cardiac scan is an effective screening method, according to the study. Meanwhile, mammography is more accepted — it is recommended annually for women over 40 years of age, and every other year for women 50 to 75 years old and women at high risk for breast cancer. Digital mammography in particular is more sensitive to the presence of calcifications, researchers said in a statement.

"Many women, especially young women, don't know the health of their coronary arteries," Dr. Harvey Hecht, lead author of the study and director of cardiovascular imaging at Mount Sinai St. Luke's hospital, said in a news release. "Based on our data, if a mammogram shows breast arterial calcifications it can be a red flag — an 'aha' moment — that there is a strong possibility she also has plaque in her coronary arteries.

For the study, researchers recruited a total of 292 women who had mammography and CT scans done within the past 12 months. Of those, 42.5 percent had calcium deposits show up on their mammogram. And 70 percent of women with these deposits also had calcium on their CT scans. Overall, 63 percent of those with breast calcification also had arterial calcification.

Researchers found that women with calcium deposits in their breast tissue were more likely to be older, have high blood pressure, and were less likely to be smokers. Interestingly, they also found that younger patients — those under 60 — had fewer false positives. If a younger woman had breast calcification, there was an 83 percent chance she also had calcium deposits in her coronary arteries.

Although more research and larger studies on this topic are needed to understand the significance of breast calcification, researchers said the findings show that mammograms could provide an opportunity to identify women with heart risks who ordinarily would not have been considered for cardiovascular screening.

Source: http://www.msn.com

2 New Cancer Therapies That Might Help Patients 'Live Again'



Cancer can be devastating to the individuals and families it affects. The disease alters patients' routines, roles, and relationships with others. Luckily, in the age of cancer research, millions more Americans are surviving the horrible disease, showing that you can live with cancer rather than die from it. In Big Think's latest video, 2 New Cancer Treatments That Give Patients Hope Again, medical researcher Dr David Agus explains two current revolutions in cancer therapy that could potentially eliminate all types of cancer.

The first treatment, known as immunotherapy, was successfully tested on former president Jimmy Carter. When cancer cells appear, they send out a "don't eat me" signal to the immune system. But now, there are drugs that can block that "don't eat me" signal, which allows the immune system to come in and "eat" — or attack — cancer cells. Immunotherapy has shown dramatic results with melanoma, kidney cancer, and some types of lung cancer. According to Agus, immunotherapy teaches you how to harness the power of your own immune system so that it can attack cancer on a more frequent basis than conventional chemotherapy treatments.

The second cancer treatment is known as precision, or personalized medicine. This means that if you have cancer, a doctor can take a piece of your cancer and sequence the DNA to look at which genes are “turned on” and which genes are “turned off.” The goal of this treatment is to develop a way to turn off the genes driving a particular cancer. Because this is still a developing therapy, though, it doesn't work on all patients.

"We don't have drugs to turn off every gene, but I can sequence the DNA of the cancer and develop a personalized therapy of that patient" Agus said in the video.

These new treatments reflect another way of thinking about cancer. In the 1800s, European doctors were classifying cancer by the body part it affected — hence breast cancer, prostate cancer, and lung cancer. Today, however, students and doctors are beginning to classify cancer by the genes that are driving the disease, which sometimes might apply to more than one cancer.

For Agus, “cancer is a verb and not a noun. ... You're cancering,” he said.

Cancer is something the body does, not something the body gets, he said. This philosophy provides a new way of approaching the disease, and encourages doctors to target and treat it with new, more effective therapies.

Source: http://www.msn.com

Federal officials, advocates push pill-tracking databases



WASHINGTON (AP) — The nation's top health officials are stepping up calls to require doctors to log in to pill-tracking databases before prescribing painkillers and other high-risk drugs.

The move is part of a multi-pronged strategy by the Obama administration to tame an epidemic of abuse and death tied to opioid painkillers like Vicodin and OxyContin. But physician groups see a requirement to check databases before prescribing popular drugs for pain, anxiety and other ailments as being overly burdensome.

Helping push the administration's effort forward is an unusual, multi-million lobbying campaign funded by a former corporate executive who has turned his attention to fighting addiction.

"Their role is to say what needs to be done, my role is to get it done," says Gary Mendell, CEO of the non-profit Shatterproof, which is lobbying in state capitals to tighten prescribing standards for addictive drugs.

Mendell founded the group in 2011, after his son committed suicide following years of addiction to painkillers. Previously Mendell was CEO of HEI Hotels and Resorts, which operates upscale hotels. To date, Mendell has invested $4.1 million of his own money in the group to hire lobbyists, public relations experts and 12 full-time staffers.

A new report from Shatterproof lays out key recommendations to improve prescription monitoring systems, which are currently used in 49 states.

The systems collect data on prescriptions for high-risk drugs that can be viewed by doctors and government officials to spot suspicious patterns. The aim is to stop "doctor shopping," where patients rack up multiple prescriptions from different doctors, either to satisfy their own drug addiction or to sell on the black market. But in most states, doctors are not required to check the databases before writing prescriptions.

Last week, the White House sent letters to all 50 U.S. governors recommending that they require doctors to check the databases and require pharmacists to upload drug dispensing data on a daily basis.

The databases are "a proven tool for reducing prescription drug misuse and diversion," said Michael Botticelli, National Drug Control Policy Director, in a statement.

But government health officials say virtually all state systems need improvements, including more up-to-date information.

"There isn't yet a single state in the country that has an optimal prescription drug monitoring program that works in real time, actively managing every prescription," said Dr. Tom Frieden, director of the Centers for Disease Control and Prevention, in a press conference last week.

Physicians warn about the unintended consequences of mandating use of programs that can be slow and difficult to use. Patients may face longer waits and less time with their physicians, says Dr. Steven Sacks, president of the American Medical Association.

"There really is a patient safety and quality-of-care cost when you mandate the use of tools that are not easy to use," Sacks said.

The report from Shatterproof highlights the gaps in current prescribing systems. When doctors are not required to log in, they generally only do so 14 percent of the time, according to data from Brandeis University.

The report points to positive results in seven states that have mandated database usage: Kentucky, New York, Tennessee, Connecticut, Ohio, Wisconsin and Massachusetts. In Kentucky, deaths linked to prescription opioids fell 25 percent after the state required log-ins in 2012, along with other steps designed to curb inappropriate prescribing.

The same information can be used to prevent deadly drug interactions between opioids and other common medications, including anti-anxiety drugs like Valium of Xanax.

Opioids are highly addictive drugs that include both prescription painkillers like codeine and morphine, as well as illegal narcotics, like heroin. Deaths linked to opioid misuse and abuse have increased fourfold since 1999 to more than 29,000 in 2014, the highest figure on record, according to the CDC.

Earlier this month the CDC released the first-ever national guidelines for prescribing opioids, urging doctors to try non-opioid painkillers, physical therapy and other methods for treating chronic pain.

But pain specialists fear requiring pill-tracking databases will discourage doctors from prescribing the drugs even when appropriate, leaving patients in pain. Dr. Gregory Terman says it takes him three minutes to log in to the system used in his home state of Washington.

"If it was easier to use, more people would use it," said Terman, who is president of the American Pain Society, a group which accepts money from pain drugmakers. Like many physicians, Terman says he supports the technology but doesn't think it should be required.

Last week, two states targeted by Shatterproof signed into law database-checking requirements: Massachusetts and Wisconsin. Mendell says his staffers are lobbying now in California and Maryland.

"I don't think we can afford to wait decades for this to slowly get implemented into the system," he says. "I think we need to take action now."

Source: http://www.msn.com

Thursday, March 24, 2016

Ransomware hackers take aim at Kentucky hospital



A Kentucky hospital is operating in an internal state of emergency following an attack by cybercriminals on its computer network, Krebs on Security reported.

Methodist Hospital, based in Henderson, Kentucky, is the victim of a ransomware attack in which hackers infiltrated its computer network, encrypted files and are now holding the data hostage, Krebs reported Tuesday.

The hospital has not responded to CNBC's requests for comment.

The criminals reportedly used new strain of malware known as Locky to encrypt important files. The malware spread from the initial infected machine to the entire internal network and several other systems, the hospital's information systems director, Jamie Reid, told Krebs.

"We essentially shut our system down and reopened on a computer-by-computer basis," David Park, an attorney for the Kentucky healthcare center told Krebs.

The hospital is reportedly considering paying hackers the ransom money of four bitcoins, about $1,600 at the current exchange rate, for the key to unlock the files.

The FBI is reportedly investigating and declined to comment for this story.

This is just the latest hack attack by cybercriminals using ransomware to shut down critical infrastructure, a cyber threat that the FBI warns is on the rise. "Ransomware has been around for several years, but there's been a definite uptick lately in its use by cyber criminals," the FBI warned in a January report.

In February, a California hospital paid a $17,000 ransom to get its files back. In that case, hackers shut down the internal computer system for more than a week, initially demanding a ransom of almost $3.7 million.

The way ransomware infects computers has also become more effective. When ransomware first emerged, the most common way for computers to become infected was when users opened email attachments containing the malware, the FBI reported.

"But more recently, we're seeing an increasing number of incidents involving so-called 'drive-by' ransomware, where users can infect their computers simply by clicking on a compromised website, often lured there by a deceptive e-mail or pop-up window," the FBI said in its report.

According to the FBI, the way cybercriminals are demanding payment has also changed, from prepaid cards to bitcoin. Hackers prefer bitcoin because of the anonymity the decentralized virtual currency network offers.

With ransomware attacks on critical infrastructure, cybercriminals have found a sweet spot, said security expert Ben Johnson. Hospitals, power companies and government municipalities are often more concerned with getting back online than investigating an attack. They are also often battling on aging computer operating systems with understaffed security teams.

"So they pay, thus encouraging the attackers because it is working," said Johnson, a former NSA employee and co-founder and Chief Security Strategist for Carbon Black.

"Ransomware has done its market research and found its ideal market segment," Johnson said. "Last year, it was that all your health records will be stolen, this year it's that you'll be in the hospital and all the systems will fail."

Source: http://www.msn.com

Monday, March 14, 2016

GM mosquitoes could block spread of Zika in Florida



Genetically modified mosquitoes could be released in Florida to block the spread of the Zika virus after the FDA confirmed they would cause "no significant threat to the environment".

The OX513A mosquito -- or Aedes aegypti -- is modified by British bioengineering company Oxitec, and has been approved following evaluation by the FDA on potential health and environmental impacts.

According to Oxitec, OX513A is intended to "suppress the population of that mosquito" at the release site in order to stop the transmission of diseases such as Zika, dengue and yellow fever.

The genetic modification does this by transmitting lethal genes to its offspring, which subsequently die before reaching adulthood. It has already been trialled in Brazil, Panama and the Cayman Islands, and Oxitec claims that these trials reduced the Aedes aegypti population by more than 90 percent.

Similar mosquitoes have been modified to halt the spread of malaria.

The FDA said in a statement that the mosquitos "do not bite humans or other animals", and are therefore "not expected to have any direct impacts on human or animal health".

"The Aedes aegypti mosquito represents a significant threat to human health," said Hadyn Parry, chief executive of Oxitec, in a statement. "In many countries it's been spreading Zika, dengue and chikungunya viruses."

"The mosquito is non-native to the US and difficult to control, with the best available methods only able to reduce the population by up to 50 percent, which is simply not enough," Parry continued. "We look forward to this proposed trial and the potential to protect people from Aedes aegypti and the diseases it spreads."

The FDA will need to make a further decision before the mosquitoes are released into the environment, and will be consulting the public for thirty days before final approval.

Source: http://www.wired.co.uk

This tech tricks your brain into hearing surround sound



Ambidio wants to give stereo sound a virtual makeover. The Los Angeles-based startup, which has secured investment from Horizons Ventures and will.i.am, has developed a proprietary encoding technology that it claims can turn stereo speakers into surround sound.

Laptops, mobile phones, tablets and even high-end hi-fi systems all work with the process. For best experience, the company says, use a laptop with speakers rather than headphones.

There’s been no shortage of stereo enhancement technologies over the years, but few have gained commercial traction. Complex recording requirements and encoding are the usual stumbling blocks.

But Ambidio looks to be different. It can be applied to any stereo source, embedded directly into movie and audio files, or used as a plug-in to process sound in real time. Adding heavyweight credibility is Skywalker Sound, which has signed up as a "strategic advisor."

Ambidio is the brainchild of Iris Wu, who as a student studying sound technology at New York University found herself increasingly frustrated at the inadequacies of laptop audio. And Michael Bay’s Transformers proved the final straw.

"There were buildings falling down, robots running around, but compared to all this visual impact, the sound from my laptop was so tinny," Wu tells WIRED. "I began to think about how I could get better sound from such a little device."

While similar to the Head Related Transfer Function trickery employed by binaural recordings, the technology is different, insists Wu. "Ambidio doesn't emulate any kind of HRTFs. We don't simulate virtual ears, virtual speakers, and we don't use HRTF shapes like EQ either. The theory behind Ambidio is a bit out-of-box - we try to let the brains pick up the sound source itself, just like we do everyday."

Ambidio claims it can make stereo sound seem three times ‘wider’ than existing virtual loudspeaker solutions. This is as much about neuroscience as it is conventional high-fidelity.

"We try to understand the whole process, how the brain interprets sound events. For example, we actually keep monitoring the environmental sound all the time, and have the ability to choose what we want to focus on, and what we don't. Knowing these really help us to fine tune Ambidio, not only make the effect more compelling, but also make it work for everyone."

"The beauty of Ambidio is that it can provide a theatrical experience to any device – from VR headsets to soundbars," says Wu. "There’s nothing like that in the market right now."

Source:http://www.wired.co.uk

Friday, March 11, 2016

Google Joins Effort to Stop Zika Virus Spread



Google last week announced it would contribute US$1 million to the UN Children's Fund to support the global fight against the mosquito-borne Zika virus.

A team of Google engineers has volunteered to work with UNICEF to analyze data in an effort to figure out the viral infection's path. It also will match employee donations with the goal of giving an extra $500,000 to UNICEF and the Pan American Health Organization.

The company took the actions following recent Zika virus outbreaks that caused a 3,000 percent increase in global search interest since November.

Last month, the World Health Organization declared a public health emergency. Coordinated Effort

The possible correlation with Zika, microcephaly and other birth defects is alarming, Google said. Four out of five people with the virus don't show any symptoms, and the primary transmitter, the Aedes mosquito, is widespread and challenging to eliminate.


UNICEF is working with Google engineers and data scientists to create an open source information platform to help UNICEF and partners on the ground target Zika response efforts, according to Chris Fabian, colead of UNICEF's innovation unit.

"This open source platform will be able to process information like mobility patterns and weather data to build risk maps. We plan to prototype this tool in the Zika response but expand it for use globally," he told TechNewsWorld.

Open Source Platform

The plan calls for Google software engineers John Li and Zora Tung, along with UNICEF research scientist Manuel Garcia Herranz and UX designer Tanya Bhandari, to work on the open source data platform. It will process data from different sources, such as weather and travel patterns, to visualize potential outbreaks.

Ultimately, the goal of the platform is to identify the risk of Zika transmission for different regions and help UNICEF, governments and nongovernmental organizations decide how and where to focus their time and resources. If successful, it can be applied to other outbreaks.

"Financial contributions and donations are always beneficial, but it is hard to say whether or not tracking the virus itself will have significant contributions," said Sarah Lisovich, content strategist at CIA Medical.

Putting Analytics to Work

The symptoms are similar to those of other common healthcare conditions, she told TechNewsWorld.

Google is a leader in terms of research tools and putting forth tools to help understand the outbreak and bring more awareness and comprehension, Lisovich added.

Analytics has been used to track mosquito-borne illnesses such as malaria, dengue fever and West Nile virus for years, according to Jamie Powers, health industry consultant at SAS Institute. In addition to understanding and learning from past events, analytics can quickly create new knowledge from billions of data points and multiple disparate data sets to provide the best input for predictive analytics.

"Text mining and social media analysis to track specific disease symptoms -- syndromic surveillance -- can also help detect the earliest stages of infectious-disease outbreaks, whether it is measles, H1N1, Ebola ... or Zika," he told TechNewsWorld. Respected Efforts

Google's contribution to the epidemiology of the Zika virus is a critical initial step for public health. It is significant not only for tracking the spread of the virus but for providing the public with information on it, said David Eling, director of business development at ProSci.

Empowering people with knowledge of where Zika is prevalent, how it is transmitted, and methods of minimizing risk is a critical job, he told TechNewsWorld.

"The more we know about the Zika virus, the more ways we will have to combat it," Eling said. "I have confidence that with this support and our growing knowledge that we will develop both a vaccine as well as a therapeutic against Zika."

Source: http://www.technewsworld.com

Wednesday, March 9, 2016

Obama Pushes Plan to Cut Medicare Drug Payments



WASHINGTON—The Obama administration is proposing a test program to see if lowering reimbursements for drugs administered by some Medicare doctors would prompt them to choose lower-cost, but equally effective, medications.

The development could lead to an overhaul of reimbursements under Medicare Part B, a program that pays about $19 billion a year to providers—and is outlined in a proposed rule issued Tuesday by the Centers for Medicare and Medicaid Services, which runs the program.

The initiative is part of a strategy by the Obama administration and Congressional lawmakers to tackle health-care spending that is driven in part by rising prescription-drug prices, an issue that has loomed in the presidential race and ranks high among public concerns in polls. The administration has sought information on pricing from pharmaceutical companies and has been probing ways to help consumers keep their drug costs in check.

But the proposal is meeting stiff opposition from the pharmaceutical industry and some providers—especially cancer centers where many high-price specialty drugs are used—because of the proposed drop in reimbursement.

“It is inappropriate for CMS to manipulate choice of treatment for cancer patients using heavy-handed reimbursement techniques,” said Dr. Allen Lichter, chief executive officer of the American Society of Clinical Oncology, a professional organization. “Physicians did not create the problem of drug pricing and its solution should not be on their backs.”

About 100 industry and consumer groups are already pressing the administration to withdraw the proposal because they say it would prevent some patients getting medications they need. They called the proposed rule “misguided and ill-considered” according to a letter sent to the Department of Health and Human Services last week in anticipation of the proposal.

“We urge you to ensure that our nation’s oldest and sickest patients continue to be able to access their most appropriate drugs and services,” according to the letter, which was signed by oncology, HIV and urology organizations.

The rule creating the test program could go into effect in two phases after a 60-day comment period, officials said. It would run for five years. Nothing in the proposal would prevent doctors from prescribing treatments they think patients need, officials said Tuesday.

“These models would test how to improve Medicare beneficiaries’ care by aligning incentives to reward value and the most successful patient outcomes,” said Dr. Patrick Conway, deputy administrator for innovation and quality and chief medical officer at CMS.

He said nothing would prevent doctors from administering any drug.

The insurance industry’s main trade group indicated support. “This pilot program is an important start towards ensuring that patients get the best value for their health-care dollars,” said Clare Krusing, a spokeswoman with America’s Health Insurance Plans.

Total drug spending in the U.S. is expected to hit $535 billion in 2018, which is almost 17% of all personal health-care spending, according to a report Tuesday by HHS.

Medicare Part B is a program that reimburses providers who administer prescription drugs in offices and hospital outpatient settings. It is a major component of Medicare, the $600 billion federal health-coverage program for roughly 50 million seniors age 65 and older and the disabled.

The Part B program has seen rising expenses due, in part, to the advent of newer and costlier prescriptions. Analysts have said the program is ripe for an overhaul because its reimbursement system provides an incentive for doctors to select more expensive drugs when cheaper and just as effective alternatives exist.

Generally, under Medicare Part B, doctors are reimbursed the average sale price of a drug plus an additional 6% premium. Critics have said this encourages the use of costlier drugs as doctors get larger reimbursements for using them.

A doctor who administers a $100 cancer drug, for example, would be reimbursed that average sales price plus $6.00. A doctor who administers a $1,000 cancer drug would be reimbursed the average sales price plus a $60 premium.

A November 2015 report by the U.S. Government Accountability Office said the current system has led to concerns that it is creating “incentives for use of higher prices drugs when lower priced alternatives are available.”

Under the proposed rule, the Obama administration would assign providers to groups based on their service areas. Doctors in certain groups would get the average sales price of the drug. They would also get a 2.5% premium instead of the current 6%. And they would get an additional fee of $16.80.

So doctors in the test ZIP codes who use a $100 drug would get the average sales price plus $19. A doctor who selects a more expensive drug at $1,000 would get about $42 plus $1,000. While the doctor who chooses the more expensive drug would still get a larger reimbursement, it would be significantly lower than the doctor would get under the current system. The goal is to reduce the incentive to provide costlier medications.

Phase two of the proposal—which would go into effect no earlier than January 2017—would alter other variables.

Some doctors under the current system and the proposed test would get a higher reimbursement rate if they select a drug that is very effective at treating a condition. They would get a lower rate if they select a drug that is less effective, officials said. Specific drugs involved would be selected based on clinical analysis with external input.

Another test in phase two would examine the impact that patients’ out-of-pocket costs have on the decision to administer drugs. Currently, about 20% of patients on Medicare Part B pay about 20% of the cost of their medications. Cost sharing would be eliminated for some in the test. The administration would examine if that has an effect on the type and cost of drugs doctors and patients chose.

Drug spending in the Medicare Part B program increased from $9.4 billion in 2005 to $18.5 billion in 2014, according to HHS.

Doctors give many drugs in an office setting, including vaccinations, cancer medications, nebulizer treatments, and drugs that are injected or infused, such as specialty medications for arthritis. The pilot test will likely face resistance from cancer doctors who have been concerned about tight margins and financial pressures from higher-price infused or injected drugs. Providers may also feel they are being pressured by the federal government into selecting cheaper drugs they don’t feel are as effective.

Source: http://www.msn.com

Sunday, March 6, 2016

Fingertip surgery



A stretchable electronic sensor may replace the scalpel and other operating room tools for some surgical procedures. It lets physicians feel electronic activity and slice tissue with their fingertips. Futuristicnews.com reports that researchers at the University of Illinois, Northwestern University and Dalian (China) University of Technology changed hard semiconductors into flexible electronics “and managed to produce special materials, which could be used for surgical gloves that give their wearer an enhanced sense of touch.

” The news website states that silicon was transformed into ultrathin “nanomembranes, cut into wavy shapes and combined with a rubbery membrane.”

Source: Futuristicnews.com

A health check chair



Checking health signs such as blood pressure, temperature and mobility usually involves multiple tests and can be time-consuming. A chair developed by Sharp is equipped with multiple sensors that can measure a user’s vital signs all at once and save the data to the cloud for physicians to reference. Sharp designed the chair for patients to use at home and is considering adding a videoconferencing system so patients can visit with physicians remotely.

“Rather than people who are ill going to the doctor, our idea is for healthy people to think about how to stay healthy, prepare for any emergencies and improve their day-to-day lifestyle,” a spokesman said way back in 2013.

Source: www.diginfo.tv

The orderly robot



The UCSF Medical Center at Mission Bay now has a fleet of about two dozen Tug robots delivering drugs, linens and meals and carting away medical waste, soiled linens and trash, reports Josh Valcarcel in Wired magazine. Twenty-seven infrared and ultrasonic sensors enable the robots to avoid bumping into people or blocking their paths.

They stand back from elevators and summon them through the hospital’s Wi-Fi, using radio waves to open doors. Human staff have varied reactions to the Tugs and, in his amusing piece, Valcarcel, who grew up in the Silicon Valley, says even he finds the hospital robots “just weird.”

Source: Wired, February 2015

Battery-powered germ-killers



As the number of joint replacement surgeries grows, so do concerns about the complications of infection from antibiotic-resistant superbugs. Biomedical engineers from the North Carolina State University Department of Industrial and Systems Engineering are developing nanotechnology built directly into orthopedic implants. A battery-activated device powers an army of microscopic germ-killers to fight bacterial infections, including methicillin-resistant Staphyloccus aureus, or MRSA.

The process applies a low-intensity electrical charge to a silver titanium implant, releasing low-toxicity silver ions that kill or neutralize bacteria. The power source, similar to a watch battery, can be integrated into the implant design. The body’s own fluids act as a conducting medium between battery and silver, enabling the low-level charge.

Source: North Carolina State University’s Edward P. Fitts Department of Industrial and Systems Engineering

Press-and-print body parts



Last year, Cornell University scientists used a 3-D printer to produce an artificial ear that, according to Randy Reiland’s January 2014 report in Smithsonian.com, “looks and works like the real thing.” Reiland notes that researchers at the University of Pennsylvania and Massachusetts Institute of Technology have bioprinted blood vessels; their counterparts at Wake Forest University developed a method for printing skin cells directly onto wounds. And a company called Organovo has come up with a 3-D printed liver.

Next up? According to Bernard Meyerson, writing for weforum.com, a 4-D printer is being developed capable of creating products that can alter themselves in response to environmental change, such as heat and humidity. That could be useful for things like clothes and footwear, Meyerson points out, and also for “health care products, such as implants designed to change in the human body.”

Source: Smithsonian.com, Jan. 6, 2014; World Economic Forum, weforum.org, March 4, 2015

Google glass aids trauma care



Trauma surgeons at the Forbes Hospital Trauma Center near Pittsburgh are testing Google Glass technology using a software called VIZR, Visual Info Zonal Reminder. Google Glass is a wearable technology with an optical head-mounted display that provides information in a smartphone-like, hands-free format. Wearers communicate with the Internet via natural language voice command. At Forbes, the technology initially is being used to provide prompts during patient resuscitation based on checklists similar to those used in the aviation industry.

“With this new technology, surgeons will have hands-free, immediate access to critical information, checklists and reminders specific to injury categories that will greatly assist our efforts to provide effective, timely care that saves lives,” says Christoph R. Kaufmann, M.D., trauma medical director. For example, if a pregnant patient with injuries to the abdomen is in transport to the emergency department, the surgeon can use a voice command to access a checklist with crucial questions to ask the paramedic upon or even before the ambulance arrives.

Source: Allegheny Health Network

The Medical Technologies That Are Changing Health Care



New, eye-popping medical technology provides earlier diagnoses, personalized treatments and a breathtaking range of other benefits for both patients and health care professionals.

Not long ago, people started wearing wristbands that recorded the number of steps they took, their heart rates and sleep cycles. But if the now-ubiquitous bands and accompanying apps that stored biorhythms started out as novelties, they paved the way for a new generation of gadgets that have become serious tools to improve health care delivery and outcomes. These newfangled contraptions will change how and where care is delivered and will enable providers to stay continuously connected with patients wherever they may be — or at least connected to the devices that indicate whether a patient is abiding by prescription protocols, getting up and about safely, and eating regularly. In some cases, they may even provide an early-warning system for serious degenerative conditions like Alzheimer’s and Parkinson’s disease.

The scope of these emerging technologies is breathtaking. High-tech sensors soon will monitor the at-home cardiac patient’s heart every minute of every day. A new type of chip, embedded in a pill will be activated at the precise moment it reaches a patient’s stomach, and will confirm for the medical record that he’s taking his medications. Straight out of science fiction, new gizmos will emerge that can scan a body for a host of symptoms without poking or prodding and, in seconds, they’ll make a diagnosis.

They may sound futuristic, but many of these devices already exist and, in fact, are being supplanted by a new generation of products that do it all faster and better.

For instance, wearable techno patches now can monitor a person’s heart rate, body temperature and other vital signs — a big leap over monitors that have to be hooked up — and their results read by the patient. The data are more robust and valuable because the patches provide “continuous monitoring instead of taking a periodic snapshot,” says Sean Chai, director of innovation and advanced technology services at Kaiser Permanente.

Another sensor under development will be capable of reading biomarkers, blood-borne chemical clues that signal the levels of stress and anxiety, which can affect health as much as disease, diet and daily activity do. If the stress-level data can be synchronized with vitals such as pulse and blood pressure, a patient will receive personalized feedback on what makes her tense and which relaxation techniques work for her. Steven Steinhubl, M.D., who directs the digital medicine program at Scripps Translational Science Institute, San Diego, calls this aid to stress control “the most exciting aspect of wearables, and I’m convinced it will happen. There are a lot of hurdles to overcome before it becomes extremely functional, but the capability is remarkable.”

Menu of innovation

Pick a medical issue — congestive heart failure, diabetes, medication noncompliance, even stressful isolation — and you’ll find researchers working to solve it with remarkable new technologies. Here are some areas they’re targeting:

Heart failure

This is Medicare’s most costly diagnosis, and the mortality rate is comparable to a new cancer diagnosis. The Scripps institute is testing three types of sensors — necklace, wristband and watch — that give both the patient and the care team continuous information on how a compromised heart is functioning. Medications can be adjusted and dietary recommendations can be made in real time that are specific to the individual. The sensors replace once-daily routines such as measuring a patient’s weight for signs of water retention, an indirect rather than direct measure of heart function.

Social influences

The ability to track a patient’s movements will help providers determine how social and environmental factors affect his or her health. The Kaiser institute is evaluating products that can analyze various components of a patient’s daily routine. Where does she eat breakfast and lunch? Does he interact with other people on a regular basis, or is he generally isolated? Correlating such personal information with vital signs can produce important insights into an individual’s well-being.

Medication compliance

An ingestible — and digestible — sensor is being rolled out to record whether and when a patient takes a medication. Developed by Proteus Digital Health, London and Redwood City, Calif., the chip uses gastric fluids as a power source, which means it turns on when it reaches the stomach. The sensor transmits the identity of the medication and the time it was taken to a skin patch, which then sends that info to an app on the patient’s mobile device. The patch also detects and transmits heart rate, activity and rest.

Timely diagnosis

Diagnostic tests to detect medical problems can be expensive and time-consuming for patients, and they have to be done one by one. A nonprofit organization called the XPrize Foundation is holding a $10 million competition to find a solution. Early next year, it will choose among 10 teams of finalists from around the world who are attempting to create a “tricorder,” named for the fictional device used to diagnose ailing characters in the “Star Trek” TV series.

Approaches vary among the competing teams but, at minimum, all devices are required to continuously monitor up to five vital signs for 72 hours, says Grant Campany, the foundation’s senior director. And they must be able to identify and diagnose up to 15 conditions as varied as stroke, AIDS, pertussis and chronic obstructive pulmonary disease.

3-D printing

Every geek’s jaw dropped at the sight of the 3-D printer when it first came to market. These days, medical researchers are harnessing its potential to vastly improve patient care. For example, Kaiser Permanente’s Los Angeles Medical Center is perfecting the use of 3-D printers to produce exact, multidimensional models of trouble spots inside patients. Surgeons can scrutinize and handle the models, then simulate a variety of possible procedures before ever going into the operating room.

This technology’s potential was dramatically demonstrated when a Kaiser patient suffered a tear in the wall of his aorta, the main artery leading out of his heart. The clinical team “printed his artery in 3-D and actually went through several different scenarios on how they could insert a stent to prevent further rupture,” Chai says. “They used that in a team-based training environment to see how they could confidently proceed with some of these special procedures.” Chai compares the process with a flight simulator in which a pilot masters the intricacies of the cockpit before entering a real one. The innovation “allows us to develop a more specialized, personalized, precise treatment plan,” Chai explains. “Ultimately, that improves the quality and affordability of care.” The patient, by the way, came through the procedure fine and is recovering.

The potential and how to reach it

Much of the emerging technology is aimed at getting inside the body without actually going inside it. “There is already significant interest in noninvasive data acquisition, whether that’s light imaging or infrared or sound waves,” says Peter Reinhart, director of the Institute for Applied Life Sciences, University of Massachusetts, Amherst.

Longer-range research is focused on capturing much more sophisticated information than current products can, Reinhart says. A promising example is a patch that uses a combination of electrical and chemical signals to identify either the predisposition to or the existence of a particular disease.

That would provide an enormous advantage when it comes to illnesses that involve brain and nerve degeneration, such as Alzheimer’s, Huntington’s or Parkinson’s disease. Instead of conducting a test and comparing results with a norm, as is done today, continuous tracking of certain biomarkers would establish a personal baseline while an individual is still healthy. Readings that significantly move off the baseline would signal declining cognitive activity before symptoms ever arise, and physicians would be alerted to do further tests. “Now you get a much earlier readout that something has just changed in your body, so let’s talk to someone,” Reinhart says.

To reach that potential, three things must happen: improvements in sensor technology; better interpretation of massive amounts of data in a medically relevant, rigorous way; and development of earlier intervention strategies. “As we get better and better at this, we’re going to find that new therapeutic options are going to be open to us,” Reinhart says. “Identifying an Alzheimer’s patient at the [observable] behavioral point, when 70 percent of the brain mass has already disappeared, really limits the number of therapeutic options you can provide that patient. If you could identify someone like that seven or eight years earlier, it now opens up a very different array of intervention strategies.”

The promise of personalized medicine to meet the unique needs of individuals depends on establishing baselines for each patient. To assess anxiety, for example, “One person’s stressor is another person’s idea of just an average day,” Reinhart says. “So just differentiating across individuals will be huge.”

That’s especially true with post-traumatic stress disorder. A lot of treatments have been shown to be effective, but they work differently for different people, says the Scripps institute’s Steinhubl. The emerging sensors will provide objective evidence of when someone is getting anxious, and how activities like meditating, reading a book, taking a walk or shooting baskets can ease the anxiety. “That can and will be life-changing,” he says. — John Morrissey is a freelance writer in Chicago.

Source: http://www.sciencedaily.com

Saturday, March 5, 2016

Plane Toilet Can Kill Germs In Three Seconds



Boeing has developed an aeroplane bathroom that can automatically kill 99.9% of bacteria.

The moment someone exits the bathroom, ultraviolet (UV) lights sanitise all surfaces in just three seconds.

The toilet seat even automatically lifts so that the light can hit hard-to-reach areas.

Given that the flush button alone has more than 250 colony-forming units of bacteria per square inch, the development is likely to be welcomed by flyers.

Boeing director Jeanne Yu said: "We're trying to alleviate the anxiety we all face when using a restroom that gets a workout during a flight."

The UV light is not the A or B type used in tanning beds and growing lights, so it is safe for humans.

Engineer Jamie Childress said the system makes microbes "explode".

He said: "The UV light destroys all known microbes by literally making them explode.

"It matches the resonant frequency of the molecular bonds on the outside of the microbes."

The company has filed a patent for the self-cleaning bathroom, which also has hands-free taps and soap dispensers, hand dryers and rubbish bins.

Boeing is also looking to develop hands-free door locks, as they are also magnets for bacteria.

A vacuum-system is also being developed to suck up any waste water and spillages that end up on the floor.

The other priority is finding ways of making tray tables cleaner as they have a higher density of bacteria per square inch.

Meanwhile Airbus is developing its own bacteria-killing bathrooms in a different way - it wants to fit them out with surfaces which automatically kill germs.

Source: http://news.sky.com

Thursday, March 3, 2016

Verisante Technology Receives Purchase Order for Aura, a Revolutionary Medical Device for the Detection of Skin Cancer

Cancer detection technology specialist, Verisante Technology has confirmed that the company has won new purchase orders for Verisante Aura from the company's exclusive distributors in Canada and Europe.

According to the company, Aura is the only device that can detect all major types of skin cancer and the only device that has been developed by a government cancer agency and a leading university dermatology department.

Developed by a team of leading specialists, Aura is built to rapidly and safely aid in the detection of skin cancer when held above a suspicious mole or lesion. Even if a mole or lesion looks normal to the naked eye, an AuraScan will help your doctor identify it.

With the new purchase order sailing in, the company plans to ship Aura devices in February and the company officials said that they will update the new Aura website with a list of clinics where patients can go to request an AuraScan when installations have been completed.

"This is a significant achievement for our Company as we take this ground-breaking technology to full commercialization," said Thomas Braun, president & CEO of Verisante. "The Company has been working very closely with our distribution partners on a strategic product launch. With manufacturing of Aura™ now underway and the full support of our distributors, 2013 is already shaping up to be a very successful year for our company."

Aura is built to work like a non-invasive optical system that utilizes Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

“Aura has the potential to revolutionize the way skin cancer is diagnosed," said Dan Webb, CEO of Clarion, exclusive Canadian distributor. "Clarion is committed to bringing this life-saving technology to medical professionals across Canada."

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer

Source: http://www.healthtechzone.com

Penn State Hershey Medical Center Selects Avantas Technology for Automated Labor Management System

Avantas recently announced that it’s consulting services and Smart Square proprietary labor management software has been selected by Penn State Milton S. Hershey Medical Center. Using the company’s technology offerings, Penn State Milton S. Hershey Medical Center will create an automated labor management system.

In a statement, Sherry Kwater, Chief Nursing Officer, Penn State Hershe, said that, "When we chose Avantas as a partner, our objective was to create increased efficiencies and cost savings across our entire enterprise. Before using this automated labor management technology we didn't have an effective way to post and fill staffing needs. Smart Square allows us to have a paperless, precise, and timely staff needs posting, creating enterprise transparency and consistency, allowing us to provide cost-effective quality care to our patients."

Implementation of the Avantas Smart Square modules was first carried out in the inpatient facility by Penn State Hershey. This helped in providing the hospital with a transparent view of staffing, scheduling, and productivity at the enterprise level. Furthermore, Penn State is also implementing Avantas' HELM (Healthcare Enterprise Labor Management) methodology. HELM essentially is a proven set of strategies based on the science of workforce planning, demand forecasting and operational best practices and combined with a complete set of scheduling and staffing tools.

Sherri Luchs, Chief Administrative Officer, Penn State Hershey Medical Group said that, "Our industry is facing unprecedented change and health care organizations will be continually challenged to get the most benefit from every dollar spent. Through our partnership with Avantas, we intend to gain greater flexibility and increased efficiency to achieve maximum value to effectively meet the staffing needs of each of our practices."

To benefit from detailed and extensive analysis of the entire health system's labor workforce and operational practices, Penn State Hershey Medical Group will also be leveraging the business intelligence tools and Smart Square dashboards from Avantas. These solutions will be implemented across more than 70 practice sites of the organization.

Source: http://www.healthtechzone.com

Wanda and Dignity Health Combine Efforts on Collaborative Platform for Cancer Treatment

Wanda and Dignity Health recently launched OncoVerse, a decision-support platform that facilitates collaboration in the treatment of cancer patients. Its designers seek to make the process of defining a course of treatment more efficient, and ensure that all members of the team involved in treatment are on the same page.

San Francisco-based Wanda, Inc. is a NetScientific Inc. portfolio company that develops remote monitoring healthcare analytics for the treatment of chronic diseases. In stating its mission, Wanda paints a grim picture of future plagued with rising healthcare costs. One statistic from the World Economic Forum in particular stands out: by 2030 overall healthcare costs will result in a cumulative output loss of $47 trillion by 2030 if no changes are made to chronic disease management.

Dignity Health is a San Francisco-based health system with more than 60,000 caregivers that operate in 21 different states. The non-profit emphasizes providing affordable care to low income and underserved patients and takes a holistic approach towards how it treats patients.

Wanda supports the concept of precision care as an effective method in reducing the cost of chronic disease. Each individual patient has their own unique combination of health issues to deal with, and one-size-fits-all treatments waste time and money trying to solve the problem.

A thorough knowledge of a patient’s history and all the pieces of information that define their unique condition make it easier to customize an effective course of treatment.

This approach gets a lot of pushback however, from patients concerned about privacy and the possible misuse of their medical information. The matter of what limits should be placed on patient information is one that will probably not be resolved by companies like Wanda, but instead be fought in courts for years to come.

In working with Dignity Health to create OncoVerse, Wanda has identified other unnecessary costs that can be reduced through technology. The last thing a stage 4 cancer patient needs is to endure a treatment team that is so disorganized, the left hand doesn’t know what the right hand is doing.

Modern customer care solutions address the left-hand/right hand problem effectively because they are designed in such a way that an agent can see all the pertinent facts about a customer’s support issue and pick up where other agents left off.

OncoVerse takes a similar approach in healthcare treatment. Care givers can see what has been done to treat a patient and follow up with the right course of action. It reduces duplicated effort and in some cases the wrong effort, during treatment, resulting in significant cost savings.

It will be interesting to see what other cost-saving opportunities Wanda can identify. Healthcare makes up one-sixth of the U.S. economy and will eventually take up a bigger share unless changes are made soon in the industry.

Source: http://www.healthtechzone.com